Welcome to our dedicated page for Vivos Therapeutics SEC filings (Ticker: VVOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking FDA milestones, dentist network expansion, and royalty streams in Vivos Therapeutics filings can feel like navigating medical jargon and legalese at once. Whether you are searching for 鈥淰ivos Therapeutics insider trading Form 4 transactions鈥� before earnings or just wondering how the latest 8-K affects competitive positioning, the details are scattered across hundreds of pages.
Stock Titan resolves that pain. Our platform delivers AI-powered summaries that translate dense disclosures into clear insights, then ties every data point back to what moves VVOS shares. Need the 鈥淰ivos Therapeutics quarterly earnings report 10-Q filing鈥� distilled into key revenue shifts? Looking for 鈥淰ivos Therapeutics annual report 10-K simplified鈥� to see R&D spend or FDA regulatory pathways? We surface it instantly, alongside
- real-time alerts for 鈥淰ivos Therapeutics Form 4 insider transactions real-time鈥�
- side-by-side comparisons of each 鈥淰ivos Therapeutics proxy statement executive compensation鈥�
- concise breakdowns of 鈥淰ivos Therapeutics 8-K material events explained鈥�
Here you will find every form the company submits鈥�10-K, 10-Q, 8-K, S-1, Section 16 filings鈥攑lus AI commentary that answers the exact questions professionals ask, like 鈥渦nderstanding Vivos Therapeutics SEC documents with AI鈥� or seeking a quick 鈥淰ivos Therapeutics earnings report filing analysis.鈥� Monitor 鈥淰ivos Therapeutics executive stock transactions Form 4,鈥� follow segment revenue trends, and assess how new clinical data may reshape growth projections, all without wading through technical text. Complex filings, made clear鈥攕o you can focus on decision-making, not document hunting.
Schedule 13G filing for Vivos Therapeutics, Inc. (VVOS) discloses that individual investor Dawei Luo beneficially owns 572,016 common shares, representing 8.52 % of the outstanding class. The stake consists of 445,205 shares held directly and 126,811 shares held through wholly-owned Space Star Holding Ltd. Luo retains sole voting and dispositive power over the entire position and reports no shared power. The filing is made on a passive basis under Rule 13d-1(c); the investor certifies the shares were not acquired to influence control of the issuer. Ownership percentages are calculated against 6,717,520 shares outstanding (per the company鈥檚 May 15 2025 10-Q plus shares issued June 9 2025). No other members, subsidiaries, or group arrangements are reported, and there are no indications of additional transactions or intentions. The disclosure mainly informs the market of a new >5 % holder, which may affect float and governance considerations but contains no financial performance data.
Michael C. Skaff filed an initial Form 3 statement of beneficial ownership for Vivos Therapeutics (VVOS), reporting his position as a 10% owner. The filing details significant holdings through two investment vehicles:
Through V-CO Investors LLC:
- 514,498 shares of common stock
- Pre-Funded Warrant for 2,705,768 shares (exercise price: $0.0001, expires 2034)
- Common Stock Purchase Warrant for 3,220,266 shares (exercise price: $2.204, expires 2029)
Through V-Co Investors 2 LLC:
- 828,000 shares of common stock
- Pre-Funded Warrant for 725,258 shares (exercise price: $0.0001, expires 2035)
- Common Stock Purchase Warrant for 2,329,886 shares (exercise price: $2.23, expires 2030)
Skaff serves as Managing Director of SP Manager LLC, which manages both investment vehicles. He disclaims beneficial ownership except for his pecuniary interest.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
What is the core focus of Vivos Therapeutics Inc?
How does the company generate its revenue?
What is the Vivos System?
Who are the primary beneficiaries of Vivos Therapeutics' services?
What distinguishes Vivos Therapeutics from traditional CPAP therapies?
How does Vivos Therapeutics integrate with the healthcare ecosystem?
What market challenges does Vivos Therapeutics face?
How does Vivos Therapeutics demonstrate industry expertise?
